通用中文 | 司美替尼 | 通用外文 | Selumetinib |
品牌中文 | 品牌外文 | Koselugo | |
其他名称 | AZD6244,ARRY-142886 | ||
公司 | 阿斯利康(Astra Zeneca) | 产地 | 美国(USA) |
含量 | 10mg | 包装 | 180粒/盒 |
剂型给药 | 储存 | 室温 | |
适用范围 | 用于治疗2岁及以上的1型神经纤维瘤病(NF1)的儿童,他们患有无法通过手术完全切除的丛状神经纤维瘤 |
通用中文 | 司美替尼 |
通用外文 | Selumetinib |
品牌中文 | |
品牌外文 | Koselugo |
其他名称 | AZD6244,ARRY-142886 |
公司 | 阿斯利康(Astra Zeneca) |
产地 | 美国(USA) |
含量 | 10mg |
包装 | 180粒/盒 |
剂型给药 | |
储存 | 室温 |
适用范围 | 用于治疗2岁及以上的1型神经纤维瘤病(NF1)的儿童,他们患有无法通过手术完全切除的丛状神经纤维瘤 |
产地国家】: 美国
【处 方 药】: 是
【包装规格】: 10mg/粒,25mg/粒, 60粒/瓶
【计价单位】: 瓶
【生产厂家中文参考译名】:
阿斯利康
【生产厂家英文名】:
AstraZeneca
【原产地英文商品名】:
Koselugo
【原产地英文药品名】:
selumetinib
【中文参考商品译名】:
Koselugo胶囊
【中文参考药品译名】:
司美替尼
【司美替尼Koselugo简介】
近日,美国食品和药物管理局(FDA)批准Koselugo(selumetinib)胶囊,用于治疗2岁及以上的1型神经纤维瘤(NF1)儿童患者,这是FDA批准的首款NF1治疗药物。适用于患有症状、无法手术的丛状神经纤维瘤的儿童患者。
FDA肿瘤高级研究中心主任Richard Pazdur指出:“小儿患者第一次有了FDA批准的药物来治疗丛状神经纤维瘤,这是一种与NF1相关的罕见肿瘤”。
Koselugo(selumetinib)作为每日二次口服单药治疗的总缓解率(ORR)为66%(n=33/50),所有患者均为部分缓解(PR)。在这些患者中,82%的患者经历了持续12个月或更长时间的缓解。治疗期间PN相关症状或功能缺陷似乎有改善的趋势。
批准日期:2020年04月11日 公司:阿斯利康
Koselugo(司美替尼[selumetinib])胶囊,用于口服
美国初次批准:2020年
【司美替尼Koselugo作用机理】
Selumetinib是促分裂原激活的蛋白激酶激酶1和2(MEK1/2)的抑制剂。MEK1/2蛋白是细胞外信号相关激酶(ERK)途径的上游调节剂。MEK和ERK都是RAS调节的RAF-MEK-ERK途径的关键组成部分,该途径通常激活不同类型的癌症。
在产生神经纤维瘤并重现人类NF1基因型和表型的经过基因修饰的NF1小鼠模型中,塞卢替尼的口服给药抑制ERK磷酸化,并减少神经纤维瘤的数量,体积和增殖。
【司美替尼Koselugo适应症和用途】
KOSELUGO是一种激酶抑制剂,适用于治疗2岁及以上患有症状性,无法手术的丛状神经纤维瘤(PN)的1型神经纤维瘤病(NF1)的儿科患者。
【司美替尼Koselugo剂量和给药】
建议的剂量为25mg/m2,每天两次在空腹的地方口服。每次服药前2小时或每次服药后1小时不要进食。
对于中度肝功能不全的患者(Child-Pugh B),每天两次口服,建议剂量降至20mg/m2。尚未确定用于严重肝功能不全(Child-Pugh C)患者的推荐剂量。
【司美替尼Koselugo禁忌症】
没有。
【司美替尼Koselugo警告和注意事项】
1.心肌病:在开始治疗之前,第一年每3个月评估一次射血分数,此后每6个月评估一次,并根据临床情况进行评估。根据不良反应的严重程度,停药,减少剂量或永久终止KOSELUGO。
2.眼毒性:在开始使用KOSELUGO之前,应在治疗期间定期进行眼科评估,并检查是否有新的视觉恶化。永久终止KOSELUGO视网膜静脉阻塞(RVO)。停止使用KOSELUGO进行视网膜色素上皮脱离(RPED),用光学相干断层扫描评估监测直至解决,然后以减少的剂量恢复。
3.胃肠道毒性:建议患者在首次出现大便稀疏后立即开始服用止泻药,并增加体液摄入量。根据不良反应的严重程度,停药,减少剂量或永久终止KOSELUGO。
4.皮肤毒性:监测严重的皮疹。根据不良反应的严重程度,停药,减少剂量或永久停药。肌酐磷酸激酶(CPK)增加:CPK和横纹肌溶解可能增加。在开始KOSELUGO之前,治疗期间和临床上应定期获取血清CPK。如果发生的CPK升高,请评估横纹肌溶解或其他原因。
根据不良反应的严重程度,停药,减少剂量或永久终止KOSELUGO。
5.维生素E水平升高和出血风险:KOSELUGO胶囊含有维生素E,并且维生素E的每日摄入量超过建议或安全限值可能会增加出血的风险。并用维生素K拮抗剂或抗血小板药的患者可能会增加出血的风险。
【司美替尼Koselugo不良反应】
最常见的不良反应(≥40%)为:呕吐,皮疹(全部),腹痛,腹泻,恶心,皮肤干燥,疲劳,肌肉骨骼疼痛,发热,痤疮样皮疹,口腔炎,头痛,甲沟炎和瘙痒。
【司美替尼Koselugo药物相互作用】
1.强或中度CYP3A4抑制剂或氟康唑:避免将强或中度CYP3A4抑制剂或氟康唑与KOSELUGO并用。如果不能避免与强效或中效CYP3A4抑制剂或氟康唑合用,减低KOSELUGO的剂量。
2.强或中度CYP3A4诱导剂:避免同时使用强和中度CYP3A4诱导剂。
【司美替尼Koselugo在特定人群中的使用】
哺乳期:建议不要母乳喂养。
【司美替尼Koselugo存储】
储存在25°C(77°F); 允许在15°C到30°C(59°F到86°F)之间的偏移[请参阅USP控制的室温]。
分配原瓶。不要去除干燥剂。防止受潮。
产地国家】: 美国
【处 方 药】: 是
【包装规格】: 10mg/粒,25mg/粒, 60粒/瓶
【计价单位】: 瓶
【生产厂家中文参考译名】:
阿斯利康
【生产厂家英文名】:
AstraZeneca
【原产地英文商品名】:
Koselugo
【原产地英文药品名】:
selumetinib
【中文参考商品译名】:
Koselugo胶囊
【中文参考药品译名】:
司美替尼
【司美替尼Koselugo简介】
近日,美国食品和药物管理局(FDA)批准Koselugo(selumetinib)胶囊,用于治疗2岁及以上的1型神经纤维瘤(NF1)儿童患者,这是FDA批准的首款NF1治疗药物。适用于患有症状、无法手术的丛状神经纤维瘤的儿童患者。
FDA肿瘤高级研究中心主任Richard Pazdur指出:“小儿患者第一次有了FDA批准的药物来治疗丛状神经纤维瘤,这是一种与NF1相关的罕见肿瘤”。
Koselugo(selumetinib)作为每日二次口服单药治疗的总缓解率(ORR)为66%(n=33/50),所有患者均为部分缓解(PR)。在这些患者中,82%的患者经历了持续12个月或更长时间的缓解。治疗期间PN相关症状或功能缺陷似乎有改善的趋势。
批准日期:2020年04月11日 公司:阿斯利康
Koselugo(司美替尼[selumetinib])胶囊,用于口服
美国初次批准:2020年
【司美替尼Koselugo作用机理】
Selumetinib是促分裂原激活的蛋白激酶激酶1和2(MEK1/2)的抑制剂。MEK1/2蛋白是细胞外信号相关激酶(ERK)途径的上游调节剂。MEK和ERK都是RAS调节的RAF-MEK-ERK途径的关键组成部分,该途径通常激活不同类型的癌症。
在产生神经纤维瘤并重现人类NF1基因型和表型的经过基因修饰的NF1小鼠模型中,塞卢替尼的口服给药抑制ERK磷酸化,并减少神经纤维瘤的数量,体积和增殖。
【司美替尼Koselugo适应症和用途】
KOSELUGO是一种激酶抑制剂,适用于治疗2岁及以上患有症状性,无法手术的丛状神经纤维瘤(PN)的1型神经纤维瘤病(NF1)的儿科患者。
【司美替尼Koselugo剂量和给药】
建议的剂量为25mg/m2,每天两次在空腹的地方口服。每次服药前2小时或每次服药后1小时不要进食。
对于中度肝功能不全的患者(Child-Pugh B),每天两次口服,建议剂量降至20mg/m2。尚未确定用于严重肝功能不全(Child-Pugh C)患者的推荐剂量。
【司美替尼Koselugo禁忌症】
没有。
【司美替尼Koselugo警告和注意事项】
1.心肌病:在开始治疗之前,第一年每3个月评估一次射血分数,此后每6个月评估一次,并根据临床情况进行评估。根据不良反应的严重程度,停药,减少剂量或永久终止KOSELUGO。
2.眼毒性:在开始使用KOSELUGO之前,应在治疗期间定期进行眼科评估,并检查是否有新的视觉恶化。永久终止KOSELUGO视网膜静脉阻塞(RVO)。停止使用KOSELUGO进行视网膜色素上皮脱离(RPED),用光学相干断层扫描评估监测直至解决,然后以减少的剂量恢复。
3.胃肠道毒性:建议患者在首次出现大便稀疏后立即开始服用止泻药,并增加体液摄入量。根据不良反应的严重程度,停药,减少剂量或永久终止KOSELUGO。
4.皮肤毒性:监测严重的皮疹。根据不良反应的严重程度,停药,减少剂量或永久停药。肌酐磷酸激酶(CPK)增加:CPK和横纹肌溶解可能增加。在开始KOSELUGO之前,治疗期间和临床上应定期获取血清CPK。如果发生的CPK升高,请评估横纹肌溶解或其他原因。
根据不良反应的严重程度,停药,减少剂量或永久终止KOSELUGO。
5.维生素E水平升高和出血风险:KOSELUGO胶囊含有维生素E,并且维生素E的每日摄入量超过建议或安全限值可能会增加出血的风险。并用维生素K拮抗剂或抗血小板药的患者可能会增加出血的风险。
【司美替尼Koselugo不良反应】
最常见的不良反应(≥40%)为:呕吐,皮疹(全部),腹痛,腹泻,恶心,皮肤干燥,疲劳,肌肉骨骼疼痛,发热,痤疮样皮疹,口腔炎,头痛,甲沟炎和瘙痒。
【司美替尼Koselugo药物相互作用】
1.强或中度CYP3A4抑制剂或氟康唑:避免将强或中度CYP3A4抑制剂或氟康唑与KOSELUGO并用。如果不能避免与强效或中效CYP3A4抑制剂或氟康唑合用,减低KOSELUGO的剂量。
2.强或中度CYP3A4诱导剂:避免同时使用强和中度CYP3A4诱导剂。
【司美替尼Koselugo在特定人群中的使用】
哺乳期:建议不要母乳喂养。
【司美替尼Koselugo存储】
储存在25°C(77°F); 允许在15°C到30°C(59°F到86°F)之间的偏移[请参阅USP控制的室温]。
分配原瓶。不要去除干燥剂。防止受潮。
Generic Name: selumetinib (capsules)
Medically reviewed by Judith Stewart, BPharm Last updated on Apr 14, 2020.
What is Koselugo?Koselugo is a prescription medicine that is used to treat children 2 years of age and older with neurofibromatosis type 1 (NF1) who have plexiform neurofibromas that cannot be completely removed by surgery.
It is not known if this medicine is safe and effective in children under 2 years of age.
Before taking KoselugoBefore taking Koselugo, tell your healthcare provider about all of your medical conditions, including if you:
· have heart problems.
· have eye problems.
· are pregnant or plan to become pregnant. Koselugo can harm your unborn baby.
o Your healthcare provider should check to see if you are pregnant before you start treatment.
o Females who are able to become pregnant should use effective birth control (contraception) during treatment, and for one week after the last dose.
o Males with female partners who are able to become pregnant should use effective birth control (contraception) during treatment, and for one week after the last dose.
o Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment.
· are breastfeeding or plan to breastfeed. It is not known if Koselugo passes into your breast milk.
o Do not breastfeed during treatment, and for one week after your last dose.
o Talk to your healthcare provider about the best way to feed your baby during this time.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, or herbal supplements. Especially tell your healthcare provider if you are taking aspirin, blood thinners, or other medicines to treat blood clots. Koselugo contains vitamin E which may increase your risk of bleeding.
How should I take Koselugo?· Take Koselugo exactly as your healthcare provider tells you to.
· Do not change your dose or stop treatment unless your healthcare provider tells you to.
· Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment if you have side effects.
· Your healthcare provider will decide on the right dose based on your weight or size (body surface area) and how many capsules of Koselugo to take.
· Koselugo should be taken around the same time each day, about 12 hours apart.
· Take Koselugo capsules on an empty stomach. Do not eat food for 2 hours before your dose and 1 hour after your dose.
· Swallow the capsules whole with water. Do not chew, dissolve, or open the capsules.
· If you miss a dose, take it as soon as you remember. If it is less than 6 hours before your next scheduled dose, take your next dose at your regular time. Do not make up for the missed dose.
· If you vomit at any time after taking Koselugo, do not take an additional dose. Take your next dose at your regular time.
What should I avoid while taking Koselugo?Do not drink grapefruit juice, eat grapefruit or take supplements that contain grapefruit or St. John’s Wort during treatment with Koselugo.
Koselugo side effectsKoselugo may cause serious side effects, including:
· Heart Problems. Koselugo can lower the amount of blood pumped by your heart which is common and can also be severe. Your healthcare provider will do tests before and during treatment to check how well your heart is working. Tell your healthcare provider right away if you get any of the following signs or symptoms:
o persistent coughing or wheezing
o shortness of breath
o swelling of your ankles and feet
o tiredness
o increased heart rate
· Eye Problems. Koselugo can cause eye problems that can lead to blindness. Your healthcare provider will check your vision before and during treatment. Tell your healthcare provider right away if you get any of the following signs or symptoms:
o blurred vision
o loss of vision
o dark spots in your vision (floaters)
o other changes to your vision
· Severe diarrhea. Diarrhea is common with Koselugo and can also be severe. Tell your healthcare provider right away the first time that you get diarrhea during treatment. Your healthcare provider may give you medicine to help control your diarrhea and may tell you to drink more fluids.
· Skin Rash. Skin rashes are common with Koselugo and can also be severe. Tell your healthcare provider if you get any of the following signs or symptoms:
o rash that covers a large area of your body
o peeling skin
o blisters
· Muscle problems (rhabdomyolysis). Muscle problems are common with Koselugo and can also be severe. Treatment with Koselugo may increase the level of enzyme in your blood called creatine phosphokinase (CPK) and may be a sign of muscle damage. Your healthcare provider should do a blood test to check your blood levels of CPK before you start taking Koselugo and during treatment. Tell your healthcare provider right away if you get any of the following signs or symptoms:
o muscle aches or pain
o muscle spasms and weakness
o dark, reddish urine
Your healthcare provider may change your dose, temporarily stop, or permanently ask you to stop taking Koselugo if you have any of these side effects.
The most common side effects are:
· vomiting
· stomach pain
· nausea
· dry skin
· feeling of tiredness, weakness or lacking energy
· muscle and bone pain
· fever
· inflammation of the mouth
· headache
· redness around the fingernails
· itching
These are not all the possible side effects. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA1088.
How should I store Koselugo?· Store Koselugo at room temperature, between 68°F to 77°F (20°C to 25°C).
· The bottle of Koselugo contains a desiccant packet to reduce moisture. Do not throw away desiccant packet.
· Keep Koselugo in its original bottle.
· Keep all medicines out of the reach of children and pets.
General information about the safe and effective use of Koselugo.Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use this medicine for a condition for which it was not prescribed. Do not give it to other people, even if they have the same symptoms you have. It may harm them. You can ask your pharmacist or healthcare provider for information that is written for a healthcare professional.
What are the ingredients in Koselugo?Active ingredient: selumetinib.
Inactive ingredients:
Capsule contains: vitamin E polyethylene glycol succinate.
The 10 mg capsule shell contains: hypromellose, carrageenan, potassium chloride, titanium dioxide, carnauba wax, and purified water.
The 10 mg capsule printing ink contains: shellac, iron oxide black, propylene glycol, and ammonium hydroxide.
The 25 mg capsule shell contains: hypromellose, carrageenan, potassium chloride, titanium dioxide, FD&C blue 2, ferric oxide yellow, purified water, carnauba wax and/or corn starch.
The 25 mg printing ink contains: ferric oxide red, ferric oxide yellow, FD&C Blue 2 aluminum lake, carnauba wax, shellac, glyceryl monooleate.